Multiple myeloma-related deregulation of bone marrow-derived CD34 + hematopoietic stem and progenitor cells

Blood

Volumn 120, Issue 13, 2012, Pages 2620-2630

  Bruns, Ingmar ^a   Cadeddu, Ron Patrick ^a   Brueckmann, Ines ^b   Fröbel, Julia ^a   Geyh, Stefanie ^a   Büst, Sebastian ^a   Fischer, Johannes C ^a   Roels, Frederik ^b   Wilk, Christian Matthias ^a   Schildberg, Frank A ^c   Hünerlitürkoglu, Ali Nuri ^d   Zilkens, Christoph ^a   Jäger, Marcus ^e   Steidl, Ulrich ^f   Zohren, Fabian ^a   Fenk, Roland ^a   Kobbe, Guido ^a   Brors, Benedict ^b   Czibere, Akos ^a,g   Schroeder, Thomas ^a   Trumpp, Andreas ^b   Haas, Rainer ^a   more..

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d Lukaskrankenhaus GmbH   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CELL ADHESION; CELL CYCLE REGULATION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CYTOSKELETON; DOWN REGULATION; EXTRACELLULAR FLUID; FEMALE; GENE EXPRESSION PROFILING; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE ERYTHROID PROGENITOR; MESENCHYMAL STROMA CELL; MICROENVIRONMENT; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84866856496     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-347484     Document Type: Article

References (49)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962-2972.
2. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33. (Pubitemid 36033957)
3. Silvestris F, Cafforio P, Tucci M, Dammacco F. Negative regulation of erythroblast maturation by Fas-L(-)/TRAIL(-) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood. 2002;99(4):1305- 1313.
4. Silvestris F, Tucci M, Cafforio P, Dammacco F. Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood. 2001;97(5): 1155-1164. (Pubitemid 32183734)
5. Maes K, Nemeth E, Roodman GD, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood. 2010;116(18):3635-3644.
6. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008;322(5909):1861-1865.
7. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23(1):10-24.
8. Ramakrishnan A, Deeg HJ. A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease. Expert Opin Biol Ther. 2009(1):9:21-28.
9. Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC. The malignant clone and the bonemarrow environment. Best Pract Res Clin Haematol. 2007;20(4):597-612.
10. Qiang YW, Chen Y, Stephens O, et al. Myelomaderived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood. 2008;112(1): 196-207.
11. Moore KA, Lemischka IR. Stem cells and their niches. Science. 2006;311(5769):1880-1885.
12. Lymperi S, Ferraro F, Scadden DT. The HSC niche concept has turned 31. Has our knowledge matured? Ann N Y Acad Sci. 2010;1192:12-18.
13. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1): 3-9.
14. Bruns I, Czibere A, Fischer JC, et al. The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia. 2009;23(5):892-899.
15. Chauhan D, Singh AV, Brahmandam M, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009;16(4):309-323.
16. Paiva B, Pérez-Andrés M, Vídriales MB, et al. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia. 2011;25(4):697-706.
17. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics. 2002;18(Suppl 1):96-104.
18. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics. 2004;20(1):93-99. (Pubitemid 38088346)
19. Verma A, Deb DK, Sassano A, et al. Cuttingedge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine induced hemopoietic suppression in aplastic anemia. J Immunol. 2002;168(12):5984-5988. (Pubitemid 34620009)
20. Essers MA, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904-908.
21. Castro-Malaspina H, Gay RE, Resnick G, et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood. 1980;56(2):289-301. (Pubitemid 10043431)
22. Ito M, Hiramatsu H, Kobayashi K, et al. NOD/ SCID/cnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100(9):3175-3182. (Pubitemid 35217065)
23. Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A. 2002;99(18):11872-11877. (Pubitemid 34994491)
24. Zhou L, Nguyen AN, Sohal D, et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood. 2008;112(8):3434-3443.
25. Urashima M, Ogata A, Chauhan D, et al. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood. 1996;87(5):1928-1938. (Pubitemid 26068909)
26. HeW, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, Massague J. Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell. 2006;125(5):929-941.
27. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood. 2000;96(6):2022- 2036.
28. Ruscetti FW, Akel S, Bartelmez SH. Autocrine transforming growth factor-beta regulation of hematopoiesis: many outcomes that depend on the context. Oncogene. 2005;24(37):5751-5763. (Pubitemid 43086135)
29. Larsson J, Karlsson S. The role of Smad signaling in hematopoiesis. Oncogene. 2005;24(37): 5676-5692. (Pubitemid 43086128)
30. Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood. 2006;107(12):4589-4596. (Pubitemid 43882602)
31. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113(6):685-700. (Pubitemid 36724933)
32. Uhl M, Aulwurm S, Wischhusen J, et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 2004;64(21):7954-7961. (Pubitemid 39446929)
33. Tabata C, Tabata R, Kadokawa Y, et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol. 2007;179(1):708-714. (Pubitemid 46986590)
34. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565-1571.
35. Zorat F, Shetty V, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol. 2001;115(4):881-894. (Pubitemid 34042906)
36. Verma A, Deb DK, Sassano A, et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem. 2002;277(10):7726- 7735.
37. Isufi I, Seetharam M, Zhou L, et al. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. J Interferon Cytokine Res. 2007;27(7):543-552. (Pubitemid 47122713)
38. Pronk CJ, Veiby OP, Bryder D, et al. Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors. J Exp Med. 2011;208(8):1563-1570.
39. Jeong JY, Silver M, Parnes A, et al. Resveratrol ameliorates TNFalpha-mediated suppression of erythropoiesis in human CD34(-) cells via modulation of NF-kappaB signalling. Br J Haematol. 2011;155(1):93-101.
40. Ng F, Boucher S, Koh S, et al. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood. 2008;112(2):295-307.
41. Hayashi T, Hideshima T, Nguyen AN, et al. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res. 2004; 10(22):7540-7546. (Pubitemid 39557515)
42. Avigdor A, Goichberg P, Shivtiel S, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34- stem/progenitor cells to bone marrow. Blood. 2004;103(8):2981-2989. (Pubitemid 38451670)
43. Zö ller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11(4):254-267.
44. Bhatia R, Munthe HA, Verfaillie CM. Role of abnormal integrin- cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia progenitors. Exp Hematol. 1999; 27(9):1384-1396. (Pubitemid 29409457)
45. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005;106(6):1901-1910. (Pubitemid 41291700)
46. Oostendorp RA, Dörmer P. VLA-4-mediated interactions between normal human hematopoietic progenitors and stromal cells. Leuk Lymphoma. 1997;24(5-6):423-435. (Pubitemid 27182199)
47. Kang Y, Chen CR, Massagué J. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell. 2003; 11(4):915-926. (Pubitemid 36566314)
48. Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, et al. TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell. 2010; 18(6):655-668.
49. Barlogie B, Hall R, Zander A, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986; 67(5):1298-1301. (Pubitemid 16080597)